FierceBiotech Feb 11, 2026 ‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
FierceBiotech Feb 11, 2026 Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
FierceBiotech Feb 11, 2026 Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
FierceBiotech Feb 11, 2026 GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
FierceBiotech Feb 11, 2026 Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
FierceBiotech Feb 10, 2026 Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
FierceBiotech Feb 10, 2026 Merck teams up with British medtech to boost vaginal therapeutics delivery system
FierceBiotech Feb 10, 2026 AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
FierceBiotech Feb 10, 2026 Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
FierceBiotech Feb 10, 2026 FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
FierceBiotech Feb 9, 2026 FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils
FierceBiotech Feb 9, 2026 Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
FierceBiotech Feb 9, 2026 CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech